What factors drove the changes in AdaptHealth's revenue and profit?

What is the revenue and EPS growth rate for AdaptHealth year over year?

What does AdaptHealth do and what are its main business segments?

What were the key takeaways from AdaptHealth's earnings call?

Did AdaptHealth beat or miss consensus estimates last quarter?

What is AdaptHealth's gross profit margin?

What guidance did AdaptHealth's management provide for the next earnings period?

What were the key takeaways from AdaptHealth’s earnings call?

- **Revenue Growth**: Full-year organic growth of 1.7%, driven by sleep (4% patient census) and respiratory (record oxygen/vent census). Q4 revenue exceeded guidance.
- **Profitability**: Adjusted EBITDA of $616.7 million (19.0% margin), excluding one-time costs. 2026 EBITDA margin expected to improve by 1%.
- **Capitated Contract Impact**: 5%-6% revenue growth contribution in 2026, with smoother-than-expected Q4 2025 go-live.
- **Balance Sheet Strength**: $219.4 million free cash flow, $250 million debt reduction, upgraded credit ratings.
- **Operational Excellence**: AI pilots doubled digital engagement, centralized order intake reduced setup times by 59% in sleep.

**【CEO Summary Section】**
- **Revenue Performance**: Full-year revenue of $3.245 billion, Q4 revenue of $846.3 million, both exceeding guidance midpoints. Organic growth of 1.7% for both full year and Q4, driven by sleep health (4% patient census growth), respiratory health (record oxygen and vent patient census), and wellness at home (new starts up 6% and 5%).
- **Profitability**: Adjusted EBITDA of $616.7 million (19.0% margin) for full year, $163.1 million (19.3% margin) for Q4. Excluding $14.5 million legal settlement and $10 million capitated contract costs, EBITDA was in line with guidance.
- **Balance Sheet Strength**: Reduced debt by $250 million in 2025, free cash flow of $219.4 million. S&P and Moody's upgraded credit ratings.
- **Operational Excellence**: Centralized order intake reduced referral-to-setup times (sleep: 9 days vs. 23 in Q4 2024; vents: 3-day YoY improvement). AI pilots for sleep order intake and self-scheduling doubled myAPP users to 327,000.
- **Capitated Contract Momentum**: Largest HME industry contract with 10 million+ patients. Mid-Atlantic go-live in December 2025 achieved 98% answer rates; full ramp-up expected in 2026 with 5%-6% revenue growth contribution.

**【CFO Financial Commentary】**
- **2026 Guidance**: Net revenue $3.44-$3.51 billion (6%-8% growth), adjusted EBITDA $680-$730 million (20.3% margin), free cash flow $175-$225 million.
- **Q1 2026 Outlook**: Revenue growth 2%-3%, adjusted EBITDA margin ~16% (due to upfront capitated costs), free cash flow negative $20-$40 million.
- **Leverage Management**: Target net leverage ratio of 2.5x; reduced interest expense by $21 million YoY.
- **Capital Allocation**: $250 million debt reduction, $42 million in tuck-in acquisitions (e.g., Hawaii HME provider).

AdaptHealth Corp. (AHCO) Q4 2025 Earnings Call Transcript

- **Record Q3 Financials**: $820M revenue (+1.8% YoY), $170M EBITDA (+3.5% YoY), 20.7% margin.
- **Debt Reduction**: $225M YTD, targeting 2.5x leverage.
- **Capitated Growth**: 170K lives deal, 6-8% 2026 revenue growth.
- **AI/automation**: 5% offshore labor reduction Q3.
- **Segment Strength**: Sleep census 1.72M, Respiratory +7.8% YoY.


**【CEO Summary Section】**
- Q3 2025 revenue reached $820.3 million, up 1.8% YoY, with organic growth of 5.1% across all segments.
- Adjusted EBITDA of $170.1 million, up 3.5% YoY, with margin improving to 20.7%.
- Debt reduced by $50 million Q3, bringing total YTD reduction to $225 million, targeting 2.5x net leverage ratio.
- Launched new capitated agreement with 170,000 lives, investing in AI/automation to reduce offshore reliance by 5% Q3.
- Sleep Health census hit 1.72 million, highest in 2 years, driven by 130,000 new starts.

**【CFO Financial Commentary】**
- Sleep Health segment revenue +5.7% YoY to $354.8 million, Respiratory Health +7.8% to $177 million.
- Diabetes Health revenue +6.4% YoY, first growth since Q1 2024.
- Free cash flow $66.8 million Q3, maintaining $170-190M YTD guidance.
- 2026 revenue growth 6-8%, driven by capitated ramp and organic growth.
- 2026 EBITDA margin expected +50bps, with $200M+ annualized capitated revenue.

**【Q&A Key Highlights】**
- Capitated ramp cautious vs competitor claims, prioritizing infrastructure before patient handoffs.
- Diabetes Health retention rates stabilize, investments in pharmacy channel processing.
- Sleep Health growth to normalize post Q4 2027, with 1.8% YTD organic growth.
- CMS competitive bidding consolidation potential, AdaptHealth positioned for industry leadership.
- No material impact from recent RAC audits, steady audit frequency.


AdaptHealth Corp. (AHCO) Q3 2025 Earnings Call Transcript

- **$1B Capitated Deal Announced**: 5-year agreement with 10+ million members, targeting $200M+ annual revenue by 2026 and 10%+ of total revenue by 2027.
- **Free Cash Flow Boost**: OBBBA tax law cuts cash taxes, offsetting $20M EBITDA guidance reduction for 2025.
- **Sleep Health Recovery**: Q2 new setups highest in 2 years, driven by 33% faster setup times and expanded appointment flexibility.
- **Diabetes Turnaround**: Sequential improvement in starts and retention; expects year-over-year revenue decline to narrow in H2.
- **Debt Reduction Momentum**: Net leverage down to 2.81x, targeting 2.5x by end-2025 with $170-190M free cash flow.

**【CEO Summary Section】**
- **Q2 2025 Financial Highlights**: Revenue of $800.4 million (flat YoY excluding divestitures), adjusted EBITDA of $155.5 million (19.4% margin), and free cash flow of $73.3 million.
- **Strategic Levers**: 
  1. **Non-acquired Growth**: Signed a 5-year, $1 billion capitated agreement with a major health system, targeting 10%+ of total revenue by 2027. Sleep Health new setups hit 2-year high, Diabetes segment shows sequential improvement in starts and retention.
  2. **Profitability**: Rolling out a standard field operating model with AI-driven automation, aiming to reduce manual administrative burden and slow hiring growth.
  3. **Balance Sheet**: Reduced debt by $150 million in Q2, net leverage ratio down to 2.81x, targeting 2.5x by end-2025.
- **External Developments**: CMS proposed competitive bidding rule may pressure margins but could favor scale; OBBBA tax law cuts cash taxes and boosts free cash flow.
- **M&A Strategy**: Disciplined approach to tuck-in acquisitions, focusing on Sleep/Respiratory geographies with strong synergies.

**【CFO Financial Commentary】**
- **Segment Performance**: 
  - Sleep Health: $334.7 million (0.9% YoY growth), 128,000 new setups (highest in 2 years).
  - Respiratory Health: $170.5 million (5.6% YoY growth), record oxygen census of 329,000.
  - Diabetes Health: $145.0 million (-4.1% YoY), CGM census up YoY for 2nd consecutive quarter.
- **Profitability Trends**: Adjusted EBITDA margin declined to 19.4% (from 20.5% YoY) due to Diabetes segment challenges and Sleep Health mix shift.
- **Liquidity & Capital Allocation**: Free cash flow guidance maintained at $170-190 million; capex of $88.7 million (11.1% of revenue) to support growth.
- **Guidance Update**: Reduced 2025 adjusted EBITDA range to $642-682 million (from $660-700 million) due to infrastructure investments for the new capitated deal.

**【Q&A Key Highlights】**
- **Capitated Deal Details**: $200 million+ annual revenue by end-2026, ramping through 2026 with full service by 2027. Infrastructure investments include 1,000+ new hires, vehicle procurement, and patient equipment CapEx.
- **Sleep Health Market Share**: Improved setup times (33% faster QoQ) driving share recovery; Q2 starts up 3% YoY, with Q3+ momentum expected.
- **Competitive Bidding Strategy**: Scale and operational efficiency will mitigate margin pressure; CMS rule may consolidate industry but create opportunities for winners.
- **M&A Environment**: Small to mid-sized assets coming to market; valuations align with trailing 12-month multiples, with focus on Sleep/Respiratory tuck-ins.
- **Diabetes Outlook**: Sequential improvement in starts and retention; expects year-over-year revenue decline to narrow in H2, potentially turning positive by year-end.

AdaptHealth Corp. (AHCO) Q2 2025 Earnings Call Transcript

- **Revenue Beat Guidance**: Q1 2025 revenue exceeded midpoint by $13.1M, driven by Respiratory Health (+3.3%) and Diabetes Health sequential improvement. Adjusted EBITDA $127.9M within range.
- **Diabetes Turnaround Signs**: New starts up sequentially for 2Q, attrition rate best in 2 years. CGM adoption growth, pump business modest YoY growth.
- **Sleep Health Challenges**: Q1 new setups behind expectations, but census up 19K. Full-year guidance maintained despite Q2 margin compression.
- **Debt Reduction Progress**: $25M debt repayment in Q1, targeting 2.5x net leverage. Free cash flow guidance $180M-$220M unchanged.
- **Tariff Risk Minimal**: Most products excluded under Nairobi Protocol; manufacturers report no material impact. No guidance adjustments needed.

**【CEO Summary Section】**
- Q1 2025 revenue exceeded midpoint of guidance by $13.1 million, driven by Respiratory Health (+3.3%) and improving Diabetes Health (-8.0% YoY but sequential improvement in new starts and attrition rates). Adjusted EBITDA was $127.9 million, within guidance range, with margin at 16.4%. Free cash flow was negative $0.1 million, but on track for full-year targets.
- Strategic focus on organic growth through patient service excellence, including process improvements in CPAP order conversion and leveraging scale in managed care. Debt reduced by $25 million to $1.96 billion, with plans to further deleverage to 2.5x net leverage.
- Tariff risk assessment: Minimal impact expected, with no current adjustments to guidance. Diabetes Health segment progress seen as critical to unlocking enterprise growth.

**【CFO Financial Commentary】**
- Q1 2025 net revenue $777.9 million (-1.8% YoY), with Sleep Health (-2.8%) underperforming due to new setup delays, offset by Respiratory Health strength. Diabetes Health net revenue decline moderating, with CGM new starts improving sequentially.
- Adjusted EBITDA margin decline to 16.4% due to Sleep Health mix shift (purchase to rental) and Diabetes Health margin pressure. Free cash flow negative $0.1 million, with $180M-$220M full-year target unchanged.
- Guidance updated to reflect incontinence asset sale: Revenue $3.18B-$3.32B, adjusted EBITDA $665M-$705M. Q2 2025 revenue expected flat YoY, with margin 18.3%-19.3% due to Sleep Health mix impact and Diabetes Health contraction.

**【Q&A Key Takeaways】**
- **Diabetes Health Recovery**: Sequential improvement in new starts and attrition rates, with CGM adoption growth. Pump business showed modest YoY growth. Team execution and technology integration driving progress.
- **Sleep Health Challenges**: Underperformance in certain geographies due to slower conversion rates. Plans to address through commercial and operational improvements, with full-year guidance unchanged.
- **Tariff Impact**: Nairobi Protocol exclusions for most medical devices; manufacturers report minimal tariff risk. No expected impact on 2025 guidance.
- **Capital Allocation**: Debt reduction priority, with $25M repaid in Q1. M&A focus on tuck-in acquisitions to enhance geographic reach.
- **Managed Care Growth**: Expanding pipeline of capitated arrangements, particularly with Medicare Advantage payers, positioning for long-term margin expansion.

AdaptHealth Corp. (AHCO) Q1 2025 Earnings Call Transcript

- **Q4 Strong Cash Flow**: Free cash flow of $73M (10% YoY growth) and debt reduction of $170M highlight balance sheet strength.
- **Sleep & Respiratory Growth**: Sleep Health census up 6.5% YoY, Respiratory Health oxygen census at record 330K+ patients.
- **Diabetes Turnaround Signs**: Attrition rate lowest in 2 years, sequential new starts improvement, and $30M QoQ revenue growth.
- **Humana Contract Extension**: Multi-year capitated agreement reinforces clinical value and payer partnerships.
- **2025 Outlook**: Target 21% adjusted EBITDA margin, with Q1 2025 facing 3-4% revenue decline but improving sequentially.

**【CEO Summary Section】**
- **Q4 2024 Financial Highlights**: Revenue was flat YoY but exceeded guidance, with Sleep Health (+3.4%) and Respiratory Health (+1%) offsetting Diabetes Health decline (-7.3%). Adjusted EBITDA margin was 23.4%, and free cash flow reached $73 million, up 10% YoY.
- **Strategic Initiatives**: Progress on 5 key areas including One Adapt (standardized operations, new leadership hires), AI/automation (self-scheduling app features), clinical relevance (adherence programs), organic growth (Humana contract extension), and debt reduction ($170M YoY decline).
- **Diabetes Segment Recovery**: Attrition rate lowest in 2 years, resupply revenue beat expectations, and sequential new starts improved, signaling early progress post-operational changes.
- **Balance Sheet Strength**: Net leverage ratio of 2.8x, with plans to divest non-core assets to further improve margin and reduce debt.

**【CFO Financial Commentary】**
- **Full Year 2024 Results**: Revenue $3.26B (+1.9%), adjusted EBITDA $688.7M (+2.7%), free cash flow $235.8M. Sleep Health and Respiratory Health margins expanded, while Diabetes Health margin contracted due to lower revenue.
- **Q4 2024 Financials**: Adjusted EBITDA $200.6M, free cash flow $73.1M (vs. $41.1M guidance beat). Debt reduced by $170M YoY, net leverage ratio 2.79x.
- **2025 Guidance**: Revenue $3.22B-$3.36B (-1% to +3%), adjusted EBITDA $670M-$710M, free cash flow $180M-$220M. Q1 2025 expects revenue down 3-4% YoY due to Diabetes Health weakness and purchase/rental mix impact.

**【Q&A Key Takeaways】**
- **Diabetes Health Outlook**: Management confident in sequential improvement, with operational changes showing early signs of stabilization.
- **Capital Allocation**: Prioritize debt reduction and strategic divestitures, with modest M&A activity expected.
- **AI/automation Progress**: Self-scheduling features reducing customer service needs, with plans to expand AI-driven insights for payers.
- **Respiratory Growth Drivers**: Record oxygen census (330K+ patients) and flu season preparedness driving segment resilience.
- **Leadership Changes**: New segment GMs and AOS leader expected to enhance operational efficiency and accountability.

Actual		0.02	0.08	-0.04	0.3653	-0.08	0.2451	0.3414	0.2888	0.2034	0.1821	0.22	0.0542	0.0514	0.2277	0.4153	0.5557	0.0934	0.2165	0.2235	0.4267	0.0273	0.2179	0.2373	0.2631
Forecast		0.1203	0.1133	0.1029	0.1957	0.2509	0.2507	0.3456	0.3787	0.2055	0.2938	0.3066	0.3099	0.0969	0.1316	0.1976	0.1925	0.0476	0.1864	0.1907	0.2816	0.0472	0.1576	0.2413	0.3476
Surprise	0.00%	-83.37%	-29.39%	-138.87%	+86.66%	-131.89%	-2.23%	-1.22%	-23.74%	-1.02%	-38.02%	-28.25%	-82.51%	-46.96%	+73.02%	+110.17%	+188.68%	+96.22%	+16.15%	+17.20%	+51.53%	-42.16%	+38.26%	-1.66%	-24.31%

AHCO

AHCO fundamentals

AHCO Q4 2025 Earnings

Earnings Call

You can ask Aime

AHCO

AHCO fundamentals

AHCO Q4 2025 Earnings

Earnings Call

AHCO Earnings Call Summary for Q4/20258:30 AM on Feb 24, 2026

AHCO Earnings Call Summary for Q3/20258:30 AM on Nov 4, 2025

AHCO Earnings Call Summary for Q2/20258:30 AM on Aug 5, 2025

AHCO Earnings Call Summary for Q1/20258:30 AM on May 6, 2025

AHCO Earnings Call Summary for Q4/20248:30 AM on Feb 25, 2025

You can ask Aime